Oak Thistle LLC Has $863,000 Stock Position in Quest Diagnostics Incorporated (NYSE:DGX)

Oak Thistle LLC raised its stake in Quest Diagnostics Incorporated (NYSE:DGXFree Report) by 31.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,261 shares of the medical research company’s stock after buying an additional 1,480 shares during the period. Oak Thistle LLC’s holdings in Quest Diagnostics were worth $863,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in DGX. JPMorgan Chase & Co. boosted its position in Quest Diagnostics by 380.0% in the first quarter. JPMorgan Chase & Co. now owns 1,458,224 shares of the medical research company’s stock valued at $206,310,000 after buying an additional 1,154,403 shares in the last quarter. Norges Bank bought a new position in shares of Quest Diagnostics during the fourth quarter valued at $157,412,000. Price T Rowe Associates Inc. MD raised its stake in shares of Quest Diagnostics by 548.7% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,125,530 shares of the medical research company’s stock valued at $149,673,000 after acquiring an additional 952,037 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Quest Diagnostics by 4.8% during the first quarter. Vanguard Group Inc. now owns 14,014,030 shares of the medical research company’s stock valued at $1,917,961,000 after acquiring an additional 636,301 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in shares of Quest Diagnostics by 12.3% during the third quarter. American Century Companies Inc. now owns 3,554,517 shares of the medical research company’s stock valued at $433,153,000 after acquiring an additional 388,162 shares during the last quarter. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Trading Down 1.8 %

DGX opened at $132.33 on Wednesday. Quest Diagnostics Incorporated has a 1-year low of $119.59 and a 1-year high of $148.62. The company has a market cap of $14.70 billion, a P/E ratio of 17.67, a price-to-earnings-growth ratio of 2.87 and a beta of 0.91. The company has a fifty day moving average price of $127.78 and a two-hundred day moving average price of $130.34. The company has a current ratio of 1.31, a quick ratio of 1.20 and a debt-to-equity ratio of 0.70.

Quest Diagnostics (NYSE:DGXGet Free Report) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.15 earnings per share for the quarter, topping the consensus estimate of $2.11 by $0.04. The business had revenue of $2.29 billion for the quarter, compared to analysts’ expectations of $2.25 billion. Quest Diagnostics had a net margin of 9.23% and a return on equity of 15.79%. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.98 earnings per share. Analysts predict that Quest Diagnostics Incorporated will post 8.75 EPS for the current fiscal year.

Quest Diagnostics Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 22nd. Shareholders of record on Monday, April 8th will be given a $0.75 dividend. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.71. The ex-dividend date of this dividend is Friday, April 5th. This represents a $3.00 annualized dividend and a yield of 2.27%. Quest Diagnostics’s payout ratio is currently 37.92%.

Analyst Ratings Changes

Several equities analysts have recently issued reports on DGX shares. TheStreet downgraded shares of Quest Diagnostics from a “b-” rating to a “c” rating in a research note on Monday, February 5th. StockNews.com downgraded shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Thursday, February 1st. Truist Financial reissued a “hold” rating and set a $145.00 target price on shares of Quest Diagnostics in a research note on Wednesday, March 20th. UBS Group lifted their target price on shares of Quest Diagnostics from $135.00 to $137.00 and gave the stock a “neutral” rating in a research note on Thursday, December 7th. Finally, Jefferies Financial Group raised shares of Quest Diagnostics from a “hold” rating to a “buy” rating and lifted their target price for the stock from $140.00 to $155.00 in a research note on Wednesday, February 7th. Ten equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $144.18.

View Our Latest Research Report on Quest Diagnostics

Insiders Place Their Bets

In other news, SVP Michael E. Prevoznik sold 661 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total value of $83,378.54. Following the sale, the senior vice president now owns 40,206 shares of the company’s stock, valued at $5,071,584.84. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, SVP Michael E. Prevoznik sold 5,611 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total value of $706,312.68. Following the sale, the senior vice president now owns 38,478 shares of the company’s stock, valued at $4,843,610.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, SVP Michael E. Prevoznik sold 661 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total transaction of $83,378.54. Following the completion of the sale, the senior vice president now directly owns 40,206 shares in the company, valued at approximately $5,071,584.84. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,150 shares of company stock valued at $1,913,202. Company insiders own 0.66% of the company’s stock.

About Quest Diagnostics

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXFree Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.